EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease

Stuart H Isaacson, Peter Jenner

Clinical Parkinsonism & Related Disorders · 2025 · 12 · 100303

DOI: 10.1016/j.prdoa.2025.100303 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2025. Verfasst von Stuart H Isaacson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton FL USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin Pharmaceutical Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In levodopa treated patients with Parkinson's disease (PD), the standard approach to managing motor fluctuations is to adjust dopaminergic therapy. However, despite the availability of a wide armamentarium of dopaminergic medications, most patients treated with levodopa will still experience significant OFF time, and it is increasingly clear that motor fluctuations have a significant non-dopaminergic component. In this narrative review, we compare and contrast the therapeutic profiles of the only two non-dopaminergic medications approved in the US for the management of OFF time, namely amantadine and istradefylline. When compared against each other the two agents exemplify two different pharmacological approaches to treatment. Whereas amantadine has a multimodal pharmacology, istradefylline has highly specific actions at A2A receptors which are highly expressed in the indirect pathway of the basal ganglia. We discuss how both offer an important alternative approach to treatment, without increasing total dopaminergic load. Clinicians can also consider that amantadine and istradefylline each have overlapping indications with classic dopaminergic medications, but with distinct mechanisms of action that can complement each other to reduce motor complications in patients already being treated with other dopaminergic agents.

Schlagwörter

Stichwörter der Autor:innen

AmantadineIstradefyllineMotor fluctuationsOFF time

Autor:innen und Institutionen

  • Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton FL USA.
  • Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London London UK.

Förderung

  • Kyowa Kirin Pharmaceutical Development

Zitieren

APA

Isaacson, S. H., & Jenner, P. (2025). Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease. Clinical Parkinsonism & Related Disorders, 12, 100303. https://doi.org/10.1016/j.prdoa.2025.100303

Vancouver

Isaacson SH, Jenner P. Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 2025;12:100303. doi:10.1016/j.prdoa.2025.100303

BibTeX
@article{Isaacson2025,
  author = {Isaacson, Stuart H and Jenner, Peter},
  title = {Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson’s disease},
  journal = {Clinical Parkinsonism & Related Disorders},
  year = {2025},
  volume = {12},
  pages = {100303},
  doi = {10.1016/j.prdoa.2025.100303}
}
Kostenlos starten →